Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30744207 | 1.00 | ROCK2 (0.36) | ROCK2ROCK1MYLK4GAAICAM1 | |
| SCHEMBL23927702 | 0.91 | ROCK2 (0.37) | ROCK2ROCK1GAAALDH1A1L3MBTL1 | |
| SCHEMBL23501355 | 0.90 | ROCK2 (0.44) | ROCK2ROCK1MYLK4GAANAMPT | |
| SCHEMBL30744162 | 0.90 | ROCK2 (0.44) | ROCK2ROCK1MYLK4GAANAMPT | |
| SCHEMBL23501353 | 0.90 | ROCK2 (0.44) | ROCK2ROCK1MYLK4GAANAMPT | |
| SCHEMBL30744194 | 0.90 | ROCK2 (0.43) | ROCK2ROCK1GAAALDH1A1L3MBTL1 | |
| SCHEMBL28915354 | 0.90 | ROCK2 (0.44) | ROCK2ROCK1ALDH1A1MEN1HTT | |
| SCHEMBL23501411 | 0.90 | ROCK2 (0.43) | ROCK2ROCK1GAAALDH1A1L3MBTL1 | |
| SCHEMBL23501278 | 0.90 | ROCK2 (0.44) | ROCK2ROCK1ALDH1A1MEN1HTT | |
| SCHEMBL30744184 | 0.90 | ROCK2 (0.44) | ROCK2ROCK1ALDH1A1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | VIVAVISION (SHANGHAI) LTD (CN) | 2022-10-20 | — | — | US | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
| CN-111217834-B | Nitroxide derivatives of ROCK kinase inhibitors | 维眸生物科技（上海）有限公司 | 2021-10-26 | — | — | CN | disclosed |
| WO-2021115495-A1 | SMALL-MOLECULE SULFUR-CONTAINING HETEROCYCLIC COMPOUND | 维眸生物科技（上海）有限公司 | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | ROCK1, NOS1, ROCK2 | ROCK2 3/4885ROCK1 1/4885MYLK4 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.